Xeris Biopharma Financial Statements
NASDAQ: XERSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Xeris Biopharma revenue and earnings
In fiscal 2025, Xeris Biopharma generated $291.8 million in revenue, up 43.7% from fiscal 2024, its 5th consecutive year of revenue growth. Net income was $554,000, for a net margin of 0.2% versus a median of -85.9% in the prior 5 years. Gross margin was 85.4% (up from 81.9%) and operating margin 8.5%.
Diluted earnings per share came in at $0.00. Over the last 5 fiscal years, XERS's revenue has grown at a 70.2% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Xeris Biopharma income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 291.85M | 203.07M | 163.91M | 110.25M | 49.59M | 20.43M |
| Revenue growth (YoY) | +43.72% | +23.89% | +48.68% | +122.32% | +142.67% | — |
| Cost of Revenue | 42.57M | 36.83M | 28.64M | 22.63M | 13.32M | 9.33M |
| Gross Profit | 249.28M | 166.24M | 135.27M | 87.61M | 36.27M | 11.11M |
| Operating Expenses | 224.38M | 199.88M | 179.28M | 169.55M | 151.43M | 94.65M |
| Research & Development | 31.16M | 25.56M | 22.34M | 20.97M | 25.16M | 20.92M |
| Selling, General & Admin | 182.37M | 163.48M | 146.09M | 137.75M | 125.72M | 73.73M |
| Operating Income | 24.90M | -33.65M | -44.01M | -81.94M | -115.16M | -83.55M |
| Interest Expense | 29.08M | 30.48M | 26.61M | 14.10M | 7.18M | 10.66M |
| Other Income (Expense) | -24.34M | -23.46M | -19.49M | -14.14M | -7.57M | -7.70M |
| Pretax Income | 554.00K | -57.10M | -63.50M | -96.08M | -122.72M | — |
| Income Tax | 0 | -2.27M | -1.25M | -1.42M | 0 | -110.00K |
| Net Income | 554.00K | -54.84M | -62.26M | -94.66M | -122.72M | -91.14M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| EPS (Basic) | 0.00 | -0.37 | -0.45 | -0.70 | -1.55 | -2.14 |
| EPS (Diluted) | 0.00 | -0.37 | -0.45 | -0.70 | -1.55 | -2.14 |
| Shares Outstanding (Basic) | 160.43M | 146.77M | 137.67M | 135.63M | 79.03M | 42.64M |
| Shares Outstanding (Diluted) | 172.74M | 146.77M | 137.67M | 135.63M | 79.03M | 42.64M |
| EBITDA | 26.21M | -32.42M | -42.52M | -80.54M | -113.83M | -82.08M |
| Gross Margin | 85.41% | 81.86% | 82.52% | 79.47% | 73.14% | 54.35% |
| Operating Margin | 8.53% | -16.57% | -26.85% | -74.32% | -232.22% | -408.84% |
| Net Margin | 19.00% | -27.00% | -37.98% | -85.86% | -247.48% | -446.00% |
This table shows 6 annual periods of Xeris Biopharma's income statement, from FY 2025 back to FY 2020, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow XERS's reporting calendar. What is a income statement?